Fortis Healthcare Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
FORTIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Fortis Healthcare reported strong FY26 results with consolidated revenue of ₹9,128 crore, up 17.3% from ₹7,783 crore in FY25. Net profit grew 31.5% to ₹1,064 crore from ₹809 crore, exceeding 25% PAT growth threshold. EBITDA improved to ₹2,136 crore with margin expansion to ~23.4% from ~21.3% in prior year. The Board recommended a dividend of ₹1 per share (10% on ₹10 face value). Auditors B S R & Co. LLP issued an unmodified opinion. However, the auditor's report includes an Emphasis of Matter regarding ongoing SFIO investigation into alleged improper transactions by erstwhile promoters and a Supreme Court order directing forensic audit of RHT Health Trust transactions—both matters originating prior to 2018. The company has filed complaints with EOW against erstwhile promoters. Exceptional items of -₹222 crore include impairment reversal in an associate company and gain on Richmond Road property sale.
Strong operational performance with double-digit revenue and profit growth. However, investors should note the unresolved regulatory investigations and Supreme Court proceedings related to historical transactions, which continue to pose potential contingent risks despite clean audit opinion.